Kamada Ltd. (KMDA) to Distribute Special Dividend of $0.14 on December 9th

Kamada Ltd. (NASDAQ:KMDA) announced a special dividend on Saturday, November 7th. Shareholders of record on Thursday, November 19th will be paid a dividend of $0.14 per share by the biotechnology company on Wednesday, December 9th. The ex-dividend date is Thursday, November 19th.

Kamada has a dividend payout ratio of 30.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Kamada to earn $0.58 per share next year, which means the company should continue to be able to cover its $0.12 annual dividend with an expected future payout ratio of 20.7%.

Kamada Price Performance

Shares of KMDA traded up $0.48 during trading hours on Monday, reaching $7.71. 171,844 shares of the company’s stock traded hands, compared to its average volume of 82,330. The firm has a market capitalization of $443.36 million, a price-to-earnings ratio of 20.29, a P/E/G ratio of 0.61 and a beta of 0.90. Kamada has a twelve month low of $6.59 and a twelve month high of $9.35. The business’s fifty day simple moving average is $8.08 and its two-hundred day simple moving average is $8.00.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Monday, November 9th. The biotechnology company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.01. Kamada had a net margin of 11.60% and a return on equity of 8.37%. The business had revenue of $52.03 million during the quarter, compared to the consensus estimate of $52.51 million. On average, equities research analysts expect that Kamada will post 0.48 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Benchmark restated a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. Stifel Nicolaus set a $12.00 price objective on shares of Kamada in a research note on Monday. Weiss Ratings upgraded shares of Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 9th. William Blair set a $15.00 price objective on Kamada in a research note on Tuesday, July 21st. Finally, Wall Street Zen raised Kamada from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 15th. Four analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $13.75.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions.

Kamada’s portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.